The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment

Kast, Richard E.; Scheuerle, Angelika; Wirtz, Christian R.; Karpel-Massler, Georg; Halatsch, Marc-Eric
October 2011
Anti-Cancer Agents in Medicinal Chemistry;2011, Vol. 11 Issue 8, p756
Academic Journal
Data from past research is presented showing that neutrophils are active participants in new vessel formation in normal physiology, in proliferating human endometrium, in non-cancer pathologies as in the pannus of rheumatoid arthritis, and in various cancers, among them glioblastoma. These data show that interleukin-8 (IL-8) is a major chemokine attracting neutrophil infiltrates in these states. Since the old anti-Hansen's disease drug dapsone inhibits neutrophil migration along an IL-8 gradient towards increasing concentrations, and is used therapeutically for this attribute to good effect in dermatitis herpetiformis, bullous pemphigoid and rheumatoid arthritis, we suggest dapsone may deprive glioblastoma of neutrophil-mediated growth promoting effects. We review past research showing that vascular endothelial growth factor, VEGF, is carried predominantly intracellularly within neutrophils- only 2% of circulating VEGF is found free in serum. Based on the available evidence summarized by the authors, dapsone has a strong theoretical potential to become a useful anti-VEGF, anti-angiogenic agent in glioblastoma treatment.


Related Articles

  • Angiogenesis in Glioblastoma Multiforme: Navigating the Maze. Linkous, Amanda G.; Yazlovitskaya, Eugenia M. // Anti-Cancer Agents in Medicinal Chemistry;2011, Vol. 11 Issue 8, p712 

    Blood vessel formation is a fundamental process that occurs during both normal and pathologic periods of tissue growth. In aggressive malignancies such as glioblastoma multiforme (GBM), vascularization is often excessive and facilitates tumor progression. In an attempt to maintain tumors in a...

  • Antitumor treatment efficacy by targeting epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in an orthotopic human glioblastoma model. Yi, Diao; Hua, Tian; Lin, Huang; Kui, Chen; Ning, Lin; Wang, Zhuang // Journal of Neuro-Oncology;Aug2011, Vol. 104 Issue 1, p93 

    Using an orthotopic intracerebral model from our established HM55-BGIV-101 tumor line, we investigated the antitumor effect on the angiogenesis and growth of human glioblastoma after treatment with monoclonal antibody DC101 against the vascular endothelial growth factor receptor-2 and monoclonal...

  • Lomustine.  // Reactions Weekly;Oct2015, Vol. 1572 Issue 1, p139 

    The article presents a case study of a patient who was diagnosed with neutropenia following administration of lomustine for refractory recurrent glioblastoma.

  • Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT. Tietze, Lutz F.; Schmuck, Kianga // Current Pharmaceutical Design;11/1/2011, Vol. 17 Issue 32, p3527 

    The treatment of cancer with common anti-proliferative agents generally suffers from an insufficient differentiation between normal and malignant cells which results in extensive side effects. To enhance the efficacy and reduce the normal tissue toxicity of anti-cancer drugs, numerous selective...

  • ADAM Proteins- Therapeutic Potential in Cancer. Xinjie Lu; Dong Lu; Scully, Mike; Kakkar, Vijay // Current Cancer Drug Targets;Dec2008, Vol. 8 Issue 8, p720 

    The A Disintegrin And Metalloprotease (ADAM) proteins belong to the metzincin-superfamily of Zn-dependent metalloproteinases that shed the extracellular domains of membrane-bound growth factors, cytokines and their receptors. The latter play a central role in cell signaling and contribute a...

  • Novel Proteins and Pathways as Anti-Cancer Therapeutic Targets. Q. Ping Dou // Current Protein & Peptide Science;Sep2010, Vol. 11 Issue 6, p396 

    No abstract available.

  • Targeted delivery of a phosphopeptide prodrug inhibits the proliferation of a human glioma cell line. Kim, Sung-min; Yoon, Sun; Yim, Min; Cho, Gyunggoo; Ryu, Eun // Amino Acids;Nov2013, Vol. 45 Issue 5, p1149 

    Peptides are ideal candidates for developing therapeutics. Polo-like kinase 1 is an important regulatory protein in the cell cycle and contains a C-terminal polo-box domain, which is the hallmark of this protein family. We developed a peptide inhibitor of polo-like kinase 1 that targets its...

  • Mitosis as an anti-cancer drug target. Salmela, Anna-Leena; Kallio, Marko // Chromosoma;Oct2013, Vol. 122 Issue 5, p431 

    Suppression of cell proliferation by targeting mitosis is one potential cancer intervention. A number of existing chemotherapy drugs disrupt mitosis by targeting microtubule dynamics. While efficacious, these drugs have limitations, i.e. neuropathy, unpredictability and development of...

  • Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. Quinn, Jennifer A.; Xiaoyin Jiang, Sara; Reardon, David A.; Desjardins, Annick; Vredenburgh, James J.; Friedman, Allan H.; Sampson, John H.; McLendon, Roger E.; Herndon, James E.; Friedman, Henry S. // Journal of Neuro-Oncology;Dec2009, Vol. 95 Issue 3, p393 

    This phase II trial evaluated efficacy and safety of temozolomide (TMZ) in combination with irinotecan (CPT-11) before radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM). Prior to radiotherapy, patients were treated with a maximum of three 6-week cycles of TMZ and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics